Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC).
METHODS: In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5-19 March 2020, were treated with 'SoC' (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction).
RESULTS: Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%) vs 63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk.
CONCLUSION: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials.
| Errataetall: |
CommentIn: Ann Rheum Dis. 2022 Oct;81(10):e199. - PMID 32855151 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 79(2020), 10 vom: 30. Okt., Seite 1286-1289 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scarsi, Mirko [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.09.2020 Date Revised 12.11.2023 published: Print-Electronic CommentIn: Ann Rheum Dis. 2022 Oct;81(10):e199. - PMID 32855151 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2020-217712 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313077959 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313077959 | ||
| 003 | DE-627 | ||
| 005 | 20231225145809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2020-217712 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313077959 | ||
| 035 | |a (NLM)32732245 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scarsi, Mirko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.09.2020 | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ann Rheum Dis. 2022 Oct;81(10):e199. - PMID 32855151 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVES: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC) | ||
| 520 | |a METHODS: In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5-19 March 2020, were treated with 'SoC' (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction) | ||
| 520 | |a RESULTS: Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%) vs 63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk | ||
| 520 | |a CONCLUSION: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-inflammatory agents, non-steroidal | |
| 650 | 4 | |a antirheumatic agents | |
| 650 | 4 | |a communicable diseases, imported | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a therapeutics | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a lopinavir-ritonavir drug combination |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Colchicine |2 NLM | |
| 650 | 7 | |a SML2Y3J35T |2 NLM | |
| 700 | 1 | |a Piantoni, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Colombo, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Airó, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Richini, Donata |e verfasserin |4 aut | |
| 700 | 1 | |a Miclini, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Bertasi, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Bottone, Damiano |e verfasserin |4 aut | |
| 700 | 1 | |a Civelli, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Cotelli, Maria-Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Damiolini, Ezio |e verfasserin |4 aut | |
| 700 | 1 | |a Galbassini, Gloria |e verfasserin |4 aut | |
| 700 | 1 | |a Gatta, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Ghirardelli, Maria-Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Magri, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Malamani, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Mendeni, Monia |e verfasserin |4 aut | |
| 700 | 1 | |a Molinari, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Morotti, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Salada, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Turla, Marinella |e verfasserin |4 aut | |
| 700 | 1 | |a Vender, Angiola |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Brucato, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Franceschini, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Furloni, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Andreoli, Laura |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 79(2020), 10 vom: 30. Okt., Seite 1286-1289 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2020 |g number:10 |g day:30 |g month:10 |g pages:1286-1289 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2020-217712 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2020 |e 10 |b 30 |c 10 |h 1286-1289 | ||